New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
11:52 EDTAMGN, FNSR, ALLYThird Point discloses new stakes in Finisar, Amgen, Ally Financial
News For FNSR;AMGN;ALLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 19, 2014
09:17 EDTALLYAlly Financial exits TARP
Ally Financial announced that the U.S. Department of the Treasury has sold its remaining 54.9M shares of Ally common stock at $23.25 per share and as a result, Ally will have exited the Troubled Asset Relief Program, or TARP, upon settlement of the sale. The U.S. Treasury received $19.6B in total on the $17.2B Ally investment, which is $2.4B more than originally invested.
09:12 EDTALLYAlly Financial 54.926M share Spot Secondary priced at $23.25
Subscribe for More Information
06:32 EDTALLYAlly Financial received DOJ subpoena over subprime automotive finance
Ally Financial disclosed in a regulatory filing last night that it recently received a subpoena from the Department of Justice requesting information in connection with its investigation related to subprime automotive finance and related securitization activities. Other financial institutions have disclosed receiving similar requests earlier this year, it added. Ally Financial also announced that at the request of the DOJ, it recently entered into an agreement to voluntarily extend the statutes of limitations to allow the agency to continue its investigation of potential claims under the False Claims Act related to representations made by Ally regarding Residential Capital, the company's former mortgage subsidiary, in connection with investments in Ally made by the United States Department of the Treasury pursuant to the Troubled Asset Relief Program beginning six years ago, in December 2008.
December 18, 2014
18:22 EDTALLYOn The Fly: After Hours Movers
UP AFTER EARNINGS: Red Hat (RHT), up 9.3%... Pier 1 Imports (PIR), up 8%... NQ Mobile (NQ), up 9.3%... Cintas (CTAS), up 6.3%. ALSO HIGHER: Aratana Therapeutics (PETX), up 25.9% after candidate for dog osteoarthritis shows positive results... Ally Financial (ALLY), up 5% after announcing that it will exit the Troubled Asset Relief Program. DOWN AFTER EARNINGS: Nike (NKE), down 2.7%. ALSO LOWER: American Apparel (APP), down 2.8% after New York Post reports on takeover bid.
17:35 EDTALLYAlly Financial to exit Troubled Asset Relief Program
The U.S. Department of the Treasury launched an offering to sell its remaining 54,926,296 shares of Ally common stock. Upon completion of the transaction, Ally will exit the Troubled Asset Relief Program . Prior to this transaction, the U.S. Treasury has received $18.3B on a $17.2B investment in Ally, representing excess proceeds of $1.1B thus far.
17:22 EDTALLYAlly Financial files automatic common stock shelf
06:27 EDTAMGNAmgen's new leukemia drug to cost $178,000, Reuters reports
Subscribe for More Information
December 17, 2014
17:47 EDTAMGNAmgen raises Q1 dividend 30% to 79c per share
Subscribe for More Information
16:33 EDTALLYAlly Financial initiated with a Buy at Jefferies
Target $27.
December 11, 2014
16:03 EDTAMGNAmgen, AstraZeneca to present results from Phase 3 plaque psoriasis study
Subscribe for More Information
10:24 EDTFNSROptions with decreasing implied volatility
Subscribe for More Information
December 10, 2014
10:20 EDTFNSROptions with decreasing implied volatility
Subscribe for More Information
December 9, 2014
14:57 EDTFNSRTelecom equipment stocks rally after Verizon CFO comments on wireless CapEx
Telecom equipment stocks, which opened lower, rallied after Verizon (VZ) CFO Fran Shammo said he sees wireless CapEx continuing to trend upward. Shammo, speaking at the UBS 42nd Annual Global Media And Communications Conference, said, "The day we start to cut wireless CapEx is the day we start to wonder where the future of this industry is going." Ciena (CIEN), JDSU (JDSU), and Finisar (FNSR) all reversed earlier losses. PRICE ACTION: In afternoon trading, Ciena is up 1.5%, JDS Uniphase is up 3.8%, and Finisar is up 4.5%. Verizon, which was downgraded this morning to Neutral from Buy by RW Baird, is trading down almost 5%.
07:44 EDTAMGNAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:40 EDTAMGNAmgen presents new BLINCYTO Phase 2 study data at ASH meeting
Amgen announced that new data from a pivotal Phase 2 study evaluating BLINCYTO for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, or ALL was presented at the 56th American Society of Hematology, or ASH, Annual Meeting and Exposition. In one analysis from the '211 study, 40% of patients treated with BLINCYTO who achieved a complete remission, or CR, or complete remission with partial hematologic recovery, or CRh, were enabled to proceed to allogeneic hematopoietic stem cell transplant, or HSCT. Additionally, a secondary analysis from the study found that 82% of patients who had a CR or CRh also had a minimal residual disease, or MRD, response, a measure used to predict disease recurrence in patients with ALL. In one analysis of the '211 study, 40% of patients treated with BLINCYTO who achieved a CR or CRh were enabled to proceed to HSCT, including both patients who had received prior HSCT and patients who had not received prior HSCT. A secondary analysis of the study demonstrated that, among patients receiving BLINCYTO who had a CR or CRh and had evaluable MRD data, 82% had an MRD response, with 70% of those patients achieving a complete MRD response. Median overall survival was longer among patients who had a CR or CRh and an MRD response compared to patients who didn't have an MRD response.
December 8, 2014
16:24 EDTAMGNAmgen initiates new combination trial for talimogene laherparepvec with KEYTRUDA
Subscribe for More Information
10:20 EDTFNSROptions with decreasing implied volatility
Subscribe for More Information
09:09 EDTAMGNAmgen announces FDA approval for XGEVA
Amgen announced that the FDA has approved a new indication for XGEVA for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. XGEVA was approved and granted Orphan Drug Designation by the FDA, which is reserved for drugs that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S. HCM is a serious complication in patients with advanced cancer, including those with hematologic malignancies, and indicates poor prognosis.1,2 The condition results from cancer-driven increases in bone resorption, and if untreated, can lead to renal failure, progressive mental impairment, coma and death. The approval of XGEVA is based on positive results from an open-label, single-arm study, which enrolled patients with advanced cancer and persistent hypercalcemia after recent bisphosphonate treatment. The primary endpoint was the proportion of patients with a response, defined as albumin-corrected serum calcium <11.5 mg/dLwithin 10 days after the first dose of XGEVA. Secondary endpoints included the proportion of patients who experienced a complete response (defined as CSC <10.8 mg/dL by day 10, time to response and response duration. The study achieved its primary endpoint with a response rate at day 10 of 63.6 percent in the 33 patients evaluated. The overall complete response rate was 63.6 percent. The estimated median time to response was nine days, and the median duration of response was 104 days.4,5
09:09 EDTAMGNAmgen announces FDA approval for XGEVA
Subscribe for More Information
05:42 EDTAMGNSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use